USPH

Business Context and Reporting Period

Company: U.S. Physical Therapy, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: The Company operates 264 outpatient physical and occupational therapy clinics across 35 states. The primary business model involves subsidiary clinic partnerships where the Company typically holds a 1% general partnership interest and a 64% limited partnership interest, with managing therapists owning the remainder. The Company also manages four third-party facilities.

Key Financial Metrics

Operational Metrics: Total patient visits increased 8% to 1,206,353. Average visits per day per clinic declined to 18.9 from 19.9 in the prior year. Net patient revenue per visit increased to $96.40.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues rose 12% to $118.3 million, driven by an 8% increase in patient visits and a 4% increase in revenue per visit due to contractual fee increases.
• Profitability Decline: Despite revenue growth, Net Income declined 9% to $6.7 million. Operating income decreased 6% to $16.0 million.
• Expense Increases:
  • Salaries: Increased 13% to $59.1 million, partly due to new clinic ramp-up and a one-time $650,000 charge related to the former CEO's resignation.
  • Corporate Costs: Increased 20% to $16.8 million, driven by legal fees ($624k increase), accounting fees for Sarbanes-Oxley compliance ($470k increase), and executive recruitment.
  • Closure Costs: The Company recognized $690,000 in closure costs in 2004 (vs. $40k in 2003) related to closing nine underperforming clinics.
• Debt Elimination: The Company converted the remaining $1.7 million of its Convertible Subordinated Notes into common stock in June 2004, resulting in zero long-term debt.

Outlook, Risks, and Unusual Items

• Strategic Shift: Management is shifting focus back to the "Traditional Partnership Model" for new clinic development, citing faster ramp-up times and higher profitability compared to wholly-owned facilities.
• Medicare Limitation Risk: A moratorium on the $1,590 annual Medicare therapy limit is in place for 2004 and 2005. The limit is scheduled to be reinstated in 2006, which could adversely impact revenue if not mitigated by secondary insurance or self-pay.
• Regulatory Environment: The Company faces risks related to healthcare fraud and abuse laws (Stark Law, Anti-Kickback Statute) and HIPAA compliance. Internal controls are largely decentralized at the clinic level.
• Unusual Items:
  • Accounting Adjustment: A cumulative rent expense adjustment of approximately $254,000 was recorded in Q4 2004 following a review of lease accounting practices.
  • Stock Repurchases: The Company repurchased 373,403 shares of common stock in 2004 for $5.6 million.
• Future Accounting Impact: Adoption of SFAS 123R (Share-Based Payment) is expected in Q3 2005, which management estimates will reduce net earnings by approximately $65,000 per quarter.

Investor Verification Checklist

• Visit Trends: Verify the sustainability of the 8% visit growth given the decline in average visits per clinic (18.9 vs 19.9) and the impact of new clinic openings.
• Medicare Exposure: Assess the potential financial impact of the Medicare therapy limit reinstatement in 2006, as 21% of visits are Medicare-covered.
• Cost Control: Monitor corporate office costs, which rose significantly due to one-time executive transition costs and compliance fees, to determine if this is a recurring trend.
• Clinic Performance: Review the performance of the 35 new clinics opened in 2004 to ensure they meet profitability projections and offset the costs of the nine closed clinics.
• Debt-Free Status: Confirm the Company's ability to fund future growth and minority interest buyouts solely through operating cash flows and equity, given the elimination of long-term debt.